🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,562 results for “Cancer” Clear

  1. Tepotinib

    Serono Europe Limited

    Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification

    phase 2 small molecule active

    1 trial

  2. Tepotinib

    Merck Sharp and Dohme

    Lung Cancer

    phase 2 small molecule active

    1 trial

  3. Testosterone Enanthate 100 MG/ML Injectable Solution

    Hospital Authority, Hong Kong

    Castration-resistant Prostate Cancer

    phase 2 small molecule active

    1 trial

  4. Testosterone cypionate

    United Therapeutics Europe Ltd

    Castration Resistant Metastatic Prostate Cancer

    phase 2 small molecule completed

    1 trial

  5. Teverelix TFA

    Nordic Bioscience A/S

    Advanced prostate cancer

    phase 2 small molecule active

    1 trial

  6. Tevimbra 100 mg concentrate for solution for infusion

    Ningbo Cancer Hospital

    Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh B, ALBI grade 1 or 2 liver function, pretreated or not by tyrosine kinase inhibitors and not pretreated with immunotherapy.

    phase 2 small molecule active

    1 trial

  7. Tevimbra 100 mg concentrate for solution for infusion, Carboplatino Hikma 10 mg/ml soluzione per infusione, Cisplatino Hikma 1mg/ml concentrato per soluzione per infusione, Paclitaxel Accord Healthcare Italia 6 mg/ml, concentrato per soluzione per infusione, Pemetrexed Ever Pharma 25 mg/ml concentrato per soluzione per infusione

    Fondazione Telethon ETS

    stage III PD-L1 positive Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  8. The treatment group using pembrolizumab combined with anlotinib and radiotherapy and chemotherapy

    The First People's Hospital of Lianyungang

    Esophageal Cancer

    phase 2 small molecule active

    1 trial

  9. Timolol Micro Labs 5 mg/ml Augentropfen, Losung, Zink Verla® 10 mg, Filmtabletten, Doxy-M-ratiopharm 100 mg tabletės, Protopic 0.1% ointment, ClobeGalen 500 Mikrogramm/g Shampoo, JNJ-73841937, Dociton® 10 mg Filmtabletten, Doxy-M-ratiopharm® 100 mg Tabletten, JNJ-61186372, MINOCIN 50 mg capsule rigide, Minocyclin-ratiopharm® 100 mg Hartkapseln, Protopic 0.1% ointment, Timolol 0,5 % AT - 1 A Pharma, 5 mg/ml Augentropfen, Lösung, Doxyderma 50 mg, Opzelura 15 mg/g cream, JNJ-61186372, Chlorhexidine, Dalacin 10

    Janssen-Cilag International N.V.

    EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  10. Tipifarnib

    Kura Oncology

    Thyroid Cancer

    phase 2 small molecule completed

    1 trial

  11. Tiragolumab

    Hoffmann-La Roche

    Cervical Cancer

    phase 2 small molecule completed

    1 trial

  12. Tiragolumab, Tecentriq 1 200 mg concentrate for solution for infusion, RO7247669

    Hoffmann-La Roche

    Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

    phase 2 small molecule active

    1 trial

  13. Tislelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Cancer

    phase 2 small molecule terminated

    1 trial

  14. Tislelizumab

    The First People's Hospital of Lianyungang

    HER2-positive or Mutated Advanced Colorectal Cancer

    phase 2 small molecule active

    1 trial

  15. Tislelizumab

    BeiGene

    Cervical Cancer

    phase 2 mab completed

    1 trial

  16. Tislelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Thyroid Cancer

    phase 2 small molecule active

    1 trial

  17. Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  18. Tislelizumab combined with chemotherapy

    The First People's Hospital of Lianyungang

    Rectal Cancer

    phase 2 small molecule active

    1 trial

  19. Toripalimab

    The First People's Hospital of Lianyungang

    Small Cell Lung Cancer Limited Stage

    phase 2 small molecule terminated

    1 trial

  20. Toripalimab

    Yongchang Zhang

    Advanced Non Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  21. Toripalimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Triple-Negative Breast Cancer (TNBC)

    phase 2 small molecule active

    1 trial

  22. Toripalimab

    The First People's Hospital of Lianyungang

    Locally Advanced Colon Cancer

    phase 2 small molecule active

    1 trial

  23. Toripalimab

    Coherus Oncology

    Sinonasal Cancer

    phase 2 small molecule active

    1 trial

  24. Toripalimab

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources